Leukemia/Lymphoma
RSSArticles
-
Clinical, Biological, and Imaging Features of Intravascular Large B-Cell Lymphoma
A multicenter, retrospective cohort study of 17 patients with pathology-proven intravascular lymphoma involving the central nervous system identified “red flag” clinical features, imaging patterns, and cerebrospinal fluid characteristics that may help expedite the diagnosis of this rare, complex, and deceptive disease.
-
Revumenib Tablets (Revuforj)
The U.S. Food and Drug Administration has approved the first menin inhibitor, revumenib, for the treatment of relapsing or refractory acute leukemia with a lysine methyltransferase 2A gene (also known as the mixed lineage leukemia gene) translocation in adults and pediatric patients.
-
Brentuximab Neuropathy
Brentuximab, an antibody-drug conjugate for the treatment of lymphomas, carries a high risk of inflammatory sensory and motor neuropathies.
-
Occurrence of Second Malignancies after Treatment for Hodgkin's Lymphoma: Who's at Fault?
Capitalizing on a large cohort of British patients followed after treatment for Hodgkin's lymphoma, the risk of occurrence of second malignancy was assessed in the context of treatment with chemotherapy alone vs treatment with combined chemotherapy and radiation. -
Incidental Splenic Mass
A 61-year-old female was evaluated for intermittent upper abdominal discomfort. A non-contrast enhanced CT revealed 5x3x4 cm lesion in the spleen that appeared to be cystic. -
Allergy and Brain Tumors: Something to Sneeze At!
There have been reports over the past decade of an interesting inverse association between allergy and glioma. In the current report pooling data from four large cohorts, investigators examined (prediagnostic) immunoglobulin E levels in 169 individuals who were to develop glioma and compared these with levels in 520 matched controls. -
Reduced CNS Metastases in TKI-Treated Renal Cell Carcinoma: Data from a Retrospective Analysis
In an analysis of outcomes for patients treated at M.D. Anderson for metastatic renal cell carcinoma before and since the advent of treatment with tyrosine kinase inhibitors (TKI), the development of brain metastases was shown to be significantly reduced. The authors speculate that TKI treatment is altering the natural history of renal carcinoma. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
New recommendations for HPV vaccine; guidelines for treatment of essential tremor; updates on smoking cessation drugs; and FDA actions. -
Hot Flash Treatment: 2011
In a randomized, double-blind, placebo-controlled trial, clonidine and venlafaxine both proved superior to placebo in reducing hot flashes in breast cancer patients. The study was insufficiently powered to prove superiority of one drug over the other. However, venlafaxine produced earlier reductions and it appeared clonidine had more sustained effect (i.e., at 12 weeks of treatment).